News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello 5's again, ANT
ABSI cruisin', one of my longterm holds, ANT
ABSI new 52 hi
6,50~~ ANT
Hello 6 bucks, ANT
5,71~~ ANT
Behaves like a lowfloater should, 5,56~~ ANT
churn above 5 bucks continues, first trial update will heat this one up for sure, had a nice long weekend despite the weather, it's my cold Nordland for a reason lol, ANT
sweet vol again, 5,69~~ ANT
5,54~~ have no doubt about my 2024 stocks, ANT
Good volume so far, almost 600k shares after 150 minutes of tradin', i'll take it, ANT
the churn around 5 bucks brought strength, 5,56~~ hod so far, ANT
Double digit stock eoy or sooner: Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody
Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties
Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering
fyi ANT
VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.
"In 2023, Absci further solidified its leadership in AI-driven biologic drug discovery," said Sean McClain, Founder and CEO. "Our breakthroughs in generative AI drug creation have rapidly translated into a differentiated internal portfolio of potential best-in-class and first-in-class programs. With validating strategic industry partnerships and our recent underwritten public offering, we're poised to further advance our pipeline, enhance our AI capabilities, and expand our partnerships. These efforts reflect our commitment to innovation, promising better biologics for patients, faster."
Recent Highlights
In January, Absci presented positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody, which exhibited properties consistent with a potentially superior product profile. Based on further confirmatory studies, Absci selected a development candidate and initiated IND-enabling studies for ABS-101 in February 2024.
Completed an underwritten public offering of common stock raising gross proceeds of approximately $86.4 million. Based on the company's current plans, Absci believes its existing cash and cash equivalents and short-term investments, including the net proceeds from the recent underwritten offering of common stock, will be sufficient to fund its operations into the first half of 2027.
Entered into a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. Under the terms of the collaboration agreement, Absci is entitled to receive an upfront commitment, research and development funding, and milestone payments, collectively totaling up to $247 million, in addition to royalties on product sales.
Entered into a partnership with PrecisionLife, a leading computational biology company driving precision medicine in complex chronic diseases, to develop a joint portfolio of potential therapeutics addressing unmet medical needs.
Appointed Professor Sir Menelas “Mene” Pangalos to Absci's Board of Directors and as co-chair of Absci’s Scientific Advisory Board. Sir Mene, who has over 25 years of experience in drug discovery and development, is retiring from his position as the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, and joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned asset programs.
check it out, fyi ANT
Hello five, toyin' stopped, expectin' the same with my other long holdings, the market is bein' played by kids lol, ANT
less daily volume and green, are they done toyin'? Hmmm, thx for those 4,60's, ANT
another toy-and-short day, and, 450k shares traded after less than 2 hours, it's all in the game, ANT
ABSI 10Q due 3/21
these days are just like: "let's take it down and see how much shares we can shake/steal", if u have plenty of dry powder, u just don't mind, for some with little cash, it can be frustratin', personally i don't mind, ANT
see what i mean? 296,780 shares at 4,88, 16:56:26 afterhours , fyi ANT
since there was alot of demand on the stock placement, this is/was an excellent opportunity to buy in for those not lucky last week, i dare to say that even more shares from this lowfloater are in stronger hands now, imvho ANT
260k shares traded after 2 hours, double digit stock eoy if not sooner, some results will do the trick, imosho ANT
4,50 x 2 = 9 bucks but i have 8 bucks as my first target, ANT
5,12~~ ANT
5,11~~ ANT
5,03~~ ANT
4,99~~ ANT
4,91~~ ANT
4,80~~ If you look down 5 posts, u'll notice just how thin this gem is, ANT
Chart resettin' for the nxt runup which will crack that 6,40 (just a few days ago, silly market lol), u just got to know when to buy more, think chart, ANT
more cheapies, keep 'm comin', i'm long absi, ANT
1 million shares traded, volume intact, fyi ANT
added 5,20's, once they get the picture of "long holders", the squeeze could be phenomenal, fyi ANT
5,70~~ cruisin' on a Friday, that feelin', ANT
almost 500k shares traded after 45 minutes, me likey, ANT
ask yourself how many shares are locked already, i do think ALOT, and by deep pockets, imosho ANT
Six bucks just around the corner, fyi ANT
Awesome early volume, a keeper in my book, for sure, ANT
5,63~~ this puppy is goin' places, 8 bucks is my first target, just fyi ANT
5,54~~ ANT
Added 5,17's, thx, ANT
volume of 1 million shares will be met again today, share exchange at a higher level continues, lookin' for 5 bucks base to hold, fyi ANT
they are tryin' some megalow vol shakes, but it will only come back stronger, don't make mistakes toyin' with a lowfloatah, fyi ANT
